Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
DURHAM, N.C., June 13, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society's (AHS) 66th Annual Scientific Meeting.
- DURHAM, N.C., June 13, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society's (AHS) 66th Annual Scientific Meeting.
- The 2024 meeting will be held at the Marriott Marquis San Diego Marina, San Diego, CA from Thursday, June 13 to Sunday, June 16, 2024, including the option of participants attending virtually.
- Full abstracts are now available on the AHS website and will be published in the journal Headache®.
- Subjects View Use of STS101 Favorably: Subject Impression Data From the Phase 3 Open-Label ASCEND Study